MacroGenics

NAS:MGNX

Biotechnology

Market Cap

$820.40mm

SMALL cap

Share Price ↓

$16.50 (-1.84%)

YTD Return ↑

32.7804%

since start of 2019

P/E Ratio

—

MGNX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 2000

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company's proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company's autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

website

Source: FactSet Research Systems

Headquarters

9640 Medical Center Drive

Rockville, MD 20850-3368

1.301.251.5172

Executives

Name	Title	Gender
Leroy E. Hood, MD, PhD	Founder	Male
Scott E. Koenig, MD, PhD	President, Chief Executive Officer & Director	Male
Ezio Bonvini, MD	Chief Scientific Officer & Senior VP-Research	Male
Joseph Panigot	Vice President-Legal Affairs	Male
Robert Obst, MBA	Vice President-Human Resources & Facilities	Male
Lynn Cilinski	Treasurer, Vice President & Controller	Female
Ruedi Aebersold, PhD	Founder	Male
Alan Aderem, PhD	Founder	Male
Jeffrey V. Ravetch, MD, PhD	Founder	Male
Paulo F. Costa, MBA	Chairman	Male
James Karrels, MBA	Chief Financial Officer, Secretary & Senior VP	Male
Atul Saran	Senior Vice President & General Counsel	Male
Jon Wigginton, MD	Chief Medical Officer & SVP-Clinical Development	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

MacroGenics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

MacroGenics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

MacroGenics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

MacroGenics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

MacroGenics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

MacroGenics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

MacroGenics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

MacroGenics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

MacroGenics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

MacroGenics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

MacroGenics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

MacroGenics performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

MacroGenics - Competitors and Related Companies

How MacroGenics stacks up to its peers in the Biotechnology industry or with competing business segments.

MacroGenics

NAS:MGNX

Biotechnology

Market Cap

$820.40mm

SMALL cap

Share Price ↓

$16.50 (-1.84%)

YTD Return ↑

32.7804%

since start of 2019

P/E Ratio

—

MGNX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

Loading…